Survival distributions impact the power of randomized placebo-phase design and parallel groups randomized clinical trials

Journal of Clinical Epidemiology

Volumn 64, Issue 3, 2011, Pages 286-292

  Abrahamyan, Lusine ^a,b   Li, Chuan Silvia ^a,c   Beyene, Joseph ^a,b   Willan, Andrew R ^a,b   Feldman, Brian M ^a,b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clinical trial simulation; Power; Randomized clinical trial design; Randomized placebo phase design; Sample size; Survival distributions

Indexed keywords

PLACEBO;

ARTICLE; COMPUTER SIMULATION; MONTE CARLO METHOD; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANDOMIZED PLACEBO PHASE DESIGN; RESPONSE TIME; SAMPLE SIZE; STATISTICAL DISTRIBUTION; SURVIVAL; TREATMENT RESPONSE;

COMPUTER SIMULATION; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; RESEARCH DESIGN; SAMPLE SIZE; SURVIVAL ANALYSIS;

EID: 78751650407     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2010.02.021     Document Type: Article

References (23)

1. M.E. Haffner Adopting orphan drugs - two dozen years of treating rare diseases N Engl J Med 354 2006 445 447
2. L. Abrahamyan, S.R. Johnson, J. Beyene, P.S. Shah, and B.M. Feldman Quality of randomized clinical trials in juvenile idiopathic arthritis Rheumatology (Oxford) 47 2008 640 645
3. J.A. Smith, D.J. Thompson, S.M. Whitcup, E. Suhler, G. Clarke, and S. Smith A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis Arthritis Rheum 53 2005 18 23
4. L.C. Lovato, K. Hill, S. Hertert, D.B. Hunninghake, and J.L. Probstfield Recruitment for controlled clinical trials: literature summary and annotated bibliography Control Clin Trials 18 1997 328 352 (Pubitemid 27337023)
5. B. Wilcken Rare diseases and the assessment of intervention: what sorts of clinical trials can we use? J Inherit Metab Dis 24 2001 291 298
6. M.E. Haffner, J. Whitley, and M. Moses Two decades of orphan product development Nat Rev Drug Discov 1 2002 821 825
7. M.F. Drummond, D.A. Wilson, P. Kanavos, P. Ubel, and J. Rovira Assessing the economic challenges posed by orphan drugs Int J Technol Assess Health Care 23 2007 36 42
8. D.A. Hughes, B. Tunnage, and S.T. Yeo Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM 98 2005 829 836
9. C. McCabe, A. Tsuchiya, K. Claxton, and J. Raftery Orphan drugs revisited QJM 99 2006 341 345
10. C. McCabe, K. Claxton, and A. Tsuchiya Orphan drugs and the NHS: should we value rarity? BMJ 331 2005 1016 1019
11. A.H. Creel, E. Losina, L.A. Mandl, R.J. Marx, N.N. Mahomed, and S.D. Martin An assessment of willingness to participate in a randomized trial of arthroscopic knee surgery in patients with osteoarthritis Contemp Clin Trials 26 2005 169 178
12. P.N. Lara Jr., R. Higdon, N. Lim, K. Kwan, M. Tanaka, and D.H. Lau Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment J Clin Oncol 19 2001 1728 1733
13. S.D. Halpern Prospective preference assessment: a method to enhance the ethics and efficiency of randomized controlled trials Control Clin Trials 23 2002 274 288
14. E.H. Giannini, D.J. Lovell, E.D. Silverman, R.P. Sundel, B.L. Tague, and N. Ruperto Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group J Rheumatol 23 1996 919 924
15. B. Feldman, E. Wang, A. Willan, and J.P. Szalai The randomized placebo-phase design for clinical trials J Clin Epidemiol 54 2001 550 557 (Pubitemid 32453347)
16. L. Abrahamyan, J. Beyene, J. Feng, Y. Chon, A.R. Willan, and H. Schmeling Response times follow lognormal or gamma distribution in arthritis patients J Clin Epidemiol 63 2010 1363 1369
17. W.D. Dupont, and W.D. Plummer Jr. Power and sample size calculations. A review and computer program Control Clin Trials 11 1990 116 128
18. J.M. Lachin, and M.A. Foulkes Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification Biometrics 42 1986 507 519
19. N.H.G. Holford, M. Hale, H.C. Ko, J.-L. Steimer, L.B. Sheiner, and C.C. Peck Simulation in drug development: good practices Draft Publication of the Center for Drug Development Science (CDDS). Draft version 1.0, July 23, 1999 Accessed December 1, 2009 Available at http://bts.ucsf.edu/cdds/research/ sddgpreport.php
20. N.H. Holford, H.C. Kimko, J.P. Monteleone, and C.C. Peck Simulation of clinical trials Annu Rev Pharmacol Toxicol 40 2000 209 234
21. W.D. Dupont, and W.D. Plummer Jr. PS power and sample size program available for free on the internet Control Clin Trials 18 1997 274
22. M. Bacsafra SSP sample size and power-survival outcomes 1st ed. 1999 Johns Hopkins Baltimore, MD
23. N. Ruperto, A. Pistorio, A. Martini, R. Sigmund, G. Hanft, and S. Simianer A meta-analysis to estimate the "real" placebo effect in juvenile rheumatoid arthritis (JRA) trials Arthritis Rheum 48 Suppl 9 2003 S90 [abstract]